Updating the evidence for the effect of radiofrequency catheter ablation on left atrial volume and function in patients with atrial fibrillation: a meta-analysis

Yan Zhuang¹, Yong-hong Yong² and Ming-long Chen²
¹Intensive Care Unit, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China
²Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
Corresponding author: Ming-long Chen. Email: chenminglong2001@163.com

Summary
Objectives: To systematically review the effects of radiofrequency catheter ablation (RFCA) on left atrial (LA) size, volumes and function in patients with atrial fibrillation (AF).
Methods: We searched MEDLINE, EMBASE, ScienceDirect, Highwire, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and the reference lists of retrieved reports in July 2012.
Setting: China
Participants: Twenty-six studies (enrolling 1821 patients) were included in the final analysis.
Main outcome measures: Changes of LA size or volumes and/or function in patients with AF after RFCA.
Results: Compared to pre-ablation values, there were significant decreases in LA diameter and LA volumes at post-ablation follow-up. However, compared to pre-ablation values, there were no significant differences in LA ejection fraction/LA active emptying fraction and LA strain at post-ablation follow-up. Decreases in LA diameter and LA volumes remained significant in those without AF recurrence but not in those with AF recurrence. LA ejection fraction/LA active emptying fraction did not decrease in patients without AF recurrence, whereas they decreased in patients with AF recurrence. As for LA strain, it seems that LA strain increases in patients without AF recurrence, with less fibrosis and with more LA volumes decrease, but the differences were not significant.
Conclusions: Successful RFCA in patients with AF significantly decreases LA size and volumes and does not seem to adversely affect LA function.
Keywords
catheter ablation, atrial size, atrial volume, atrial function, atrial fibrillation

Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia. It impairs cardiac function and increases the risk of stroke. Treatments of AF include restoring normal sinus rhythm or controlling rate only and preventing thromboembolism.¹ Rate control is the preferred management option in most patients. Rhythm control is an option for patients in whom rate control cannot be achieved or who have persistent symptoms even with good rate control. Pharmacological therapy to restore and maintain sinus rhythm in some patients is often unsuccessful. For this group, catheter ablation is an important treatment option. Catheter ablation is indicated to prevent the recurrence of symptomatic AF.² Recently, clinical trials have clarified the role of catheter ablation in the treatment of AF.³ But most randomized studies only included patients with paroxysmal AF and the FDA has approved catheters for use only in such patients.⁴ However, ablation of persistent or permanent AF in symptomatic patients in whom medical therapy has failed is reasonable, since such patients have been shown to have considerable symptom relief with a successful ablation. Jeevanantham et al. had performed a meta-analysis in 2010 to assess the effects of radiofrequency catheter ablation (RFCA) on left atrial (LA) size, volumes and function and found that there were significant decreases in LA diameter and LA volumes at post-ablation follow-up. However, compared to pre-ablation values, there were no significant differences in LA ejection fraction/LA active emptying fraction at post-ablation follow-up.⁵ But the exact effects of RFCA on LA size, volumes and function in patients who undergo RFCA are not well understood.
Methods

MEDLINE, EMBASE, ScienceDirect, Highwire, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were searched before conducting the review on May 2012 to ensure that there was no recent review. The review was reported according to the PRISMA guidelines for systematic reviews.  

After scoping searches, we developed a review protocol, which described the search strategy and methods for data collection and analysis. According to review aims, search terms were generated by Patient, Intervention, Comparison and Outcome (PICOS) elements (see Table 1).

Search

We searched MEDLINE, EMBASE, ScienceDirect, Highwire, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and the reference lists of retrieved reports in July 2012 for studies of RFCA in patients with AF using the terms identified by PICOS (Table 1).

Selection

Two investigators (YZ and YHY) independently screened all titles and abstracts to identify studies that examined the effects of RFCA in patients with AF on LA size, volumes and function. Only reports in English were included in this study. Studies were excluded if the research met any one of the following criteria: (1) the effects of RFCA on LA size, volumes or ejection fraction were not reported before and after RFCA, (2) publication only as an abstract and (3) duplicate publication or ongoing/unpublished study. The inclusion/exclusion criteria for the results of our search are listed in Table 2.

Data extraction

Two reviewers (YZ and YHY) extracted relevant data from the included studies using a standardized data extraction form. Randomized and non-randomized studies with follow-up imaging done at least one month after RFCA were considered for inclusion. Primary outcome measures were changes in LA diameter (LAD), changes in LA maximum volume.

Table 1. PICOS identifiers from research questions (key terms) and database- and thesaurus-derived alternatives (additional terms) used to generate database searches.

| Participants | Interventions | Comparisons | Outcomes | Study design |
|--------------|---------------|-------------|----------|--------------|
| Key terms    | Atrial fibrillation | Catheter ablation | NA | Atrial size | NA |
|              |               |             |          | Atrial volume | |
|              |               |             |          | Atrial function | |
| Additional terms | Atrial fibrillation | Radiofrequency catheter ablation | NA | LA diameter | NA |
|                |                |               |          | LA maximum volume | |
|                |                |               |          | LA minimum volume | |
|                |                |               |          | LA ejection fraction | |
|                |                |               |          | LA active emptying fraction | |
|                |                |               |          | LA strain | |

Terms within each column were distinguished using the OR function, and the terms in different columns combined using the AND function.

Table 2. Inclusion/exclusion criteria.

| Included | Excluded |
|----------|----------|
| Studies that examined the effects of RFCA in patients with AF on LA size | The effects of RFCA on LA size, volumes, or ejection fraction were not reported before and after RFCA |
| Studies that examined the effects of RFCA in patients with AF on LA volumes | Publication only as an abstract |
| Studies that examined the effects of RFCA in patients with AF on LAEF/LAAEF. | Duplicate publication or ongoing/unpublished study |
| Studies that examined the effects of RFCA in patients with AF on LA strain | |

RFCA: radiofrequency catheter ablation; LA: left atrial; LAEF/LAAEF: LA ejection fraction/LA active emptying fraction; AF: atrial fibrillation.
(LAVmax; defined as the maximal LA volume before the opening of the mitral valve), changes in LA minimum volume (LAVmin; defined as the minimal LA volume at the closure of mitral valve), changes in LA ejection fraction (LAEF; defined as [LAVmax − LAVmin]/LAVmax), changes in LA active emptying fraction (LAAEF; defined as [LAmid-diastolic volume at onset of p wave on surface electrocardiogram − LAVmin]/LA mid-diastolic volume at onset of p wave on surface electrocardiogram) and changes in LA strain. Studies reporting changes in LAD, LA volumes and function on the basis of AF recurrence were analysed separately to assess effects of RFCA in patients with AF recurrence compared to those without AF recurrence. Studies that did not separate the results on the basis of the recurrence of AF were analysed together as combined studies. The total changes in LA size, volumes and function for all studies (recurrent, no recurrence and combined) were also analysed.

Quality assessment
The quality of included studies was assessed by exploring (1) study design, (2) the representativeness of the study participants with regard to patients who undergo RFCA for AF, (3) reporting of loss to follow-up and (4) limitations and biases.

Data synthesis
Statistical analyses were performed using RevMan version 4.2 (The Cochrane Collaboration, Oxford, England), and the results are expressed as weighted mean differences (WMDs) for continuous outcomes, with 95% confidence intervals (CIs). We calculated the $I^2$ statistic to assess the heterogeneity across the trials, and a value greater than 50% was considered substantial heterogeneity; then, data were pooled using the random-effects model. We planned to conduct sensitivity analyses if significant heterogeneity was found for any one of the outcomes. Sensitivity analyses included (1) fixed- versus random-effects model, (2) exclusion of studies with shorter durations of follow-up <3 months, (3) exclusion of studies with less than 30 patients and (4) analyses based on AF recurrence. Publication bias was explored by visual inspection of a funnel plot, and $p$ value <0.05 was used for statistical significance.

Results
We identified 26 studies (enrolling 1821 patients) that reported changes in LA size, volumes or function in patients with AF who underwent RFCA (Figure 1). Baseline characteristics of the studies included in the meta-analysis are listed in Table 3. The primary outcomes of the studies included are listed in Table 4.

Management I – interventions
All patients had undergone RFCA. There were two studies that had repeated RFCA.7,10 Liu et al. had compared different treatment strategies on left atrial size in patients with lone paroxysmal atrial fibrillation.17 Nineteen studies had included patients with paroxysmal or nonparoxysmal AF,7–9,13,16–30,32 four studies only included patients with paroxysmal AF,12,14,15,31 one study had found that ablation in no paroxysmal AF patients with heart failure and low ejection fraction could reversing atrial and ventricular remodeling.23 Nine studies had reported changes in LAD, LA volumes, or function on the basis of AF recurrence.9,11,15,17,19,23,26,27,31

Management II – outcomes
Compared to pre-ablation values, there were significant decreases in LAD (WMD = −1.52 mm, 95% CI = −2.57 to −0.47; Figure 2), LAVmax (WMD = −6.12 mL, 95% CI = −9.46 to −2.78; Figure 3) and LAVmin (WMD = −2.59 mL, 95% CI = −4.88 to −0.29; Figure 4) during follow-up after ablation therapy. However, when analysed on the basis of AF recurrence, decreases in LAD, LAVmax and LAVmin remained significant among studies which reported no AF recurrence but not in those with AF recurrence (Figures 2 to 4).

Compared to pre-ablation values, there were no significant differences in the LAEF/LAAEF (WMD = −0.58%, 95% CI = −3.64% to 2.47%; Figure 5) after RFCA during follow-up. However, when analysed on the basis of AF recurrence, there were significant decreases in the LAEF/LAAEF in patients with AF recurrence, whereas there were no significant decreases in the LAEF/LAAEF in those with no AF recurrence (Figure 5).

As for LA strain, it seems that LA strain increases in patients without AF recurrence, with less fibrosis and with more LA volumes decrease, but the differences were not significant (Figure 6).

Quality assessment of the studies
The quality of the studies analysed, using predefined criteria, showed that most of these studies were retrospective in nature and used consecutive sampling designs. Sampling bias and smaller sample sizes limited the external validity of these results.
**Heterogeneity and sensitivity analyses**

Heterogeneity was explored using sensitivity analyses. We reported the results using a random-effects model because significant heterogeneity was noted in all total outcomes. The results did not differ when analysed using a fixed-effects model.

Sensitivity analyses based on studies with ≥3 months of follow-up showed that LAD (WMD = 1.49 mm, 95% CI = 2.58 to −0.4), LAVmax (WMD = 5.47 mL, 95% CI = 8.83 to −2.11) and LAVmin (WMD = 6.23 mL, 95% CI = 9.54 to −2.91) decreased significantly after RFCA, whereas the LAEF/LAAEF (WMD = 0.12%, 95% CI = 3.45 to 3.22%) did not significantly change at follow-up after RFCA.

Sensitivity analyses on the basis of studies including ≥30 patients showed that LAD (WMD = 1.41 mm, 95% CI = 2.48 to −0.33) and LAVmax (WMD = 5.60 mL, 95% CI = 9.00 to −2.20) decreased significantly after ablation, whereas LAVmin (WMD = 2.19 mL, 95% CI = 4.54 to 0.16) and the LAEF/LAAEF (WMD = 0%, 95% CI = −3.32% to 3.31%) did not significantly change at follow-up after ablation.

**Publication bias**

On the basis of funnel plot analysis, publication bias was noted for the primary outcomes (Figure 7).

**Discussion**

**Principal findings**

Our study shows that LAD and LA volumes decrease after RFCA during follow-up. However, LA function (as measured by the LAEF/LAAEF and LA strain)
Table 3. Characteristics of studies included in the meta-analysis.

| Study                  | Number of patients | Follow-up (month) | Paroxysmal AF | Persistent AF | Permanent AF | Age (years) | Men | Duration of AF | LVEF |
|------------------------|--------------------|-------------------|---------------|---------------|--------------|--------------|-----|----------------|------|
| Montserrat et al.7     | 104                | 6                 | 54 (43%)      | 33 (32%)      | 17 (16%)     | 53 ± 11      | 81 (71%) | 52 ± 34 (m)   | 59 ± 9 |
| First RFCA             |                    |                   |               |               |              |              |     |                |      |
| Montserrat et al.7     | 50                 | 6                 | 23 (46%)      | 22 (44%)      | 5 (10%)      | 53 ± 10      | 39 (78%) | 71 ± 54 (m)   | 59 ± 10|
| Repeated RFCA          |                    |                   |               |               |              |              |     |                |      |
| Tops et al.8           | 148                | 13.2 ± 6.7        | 112 (76%)     | 36 (24%)      | NA           | 54 ± 9       | 117 (79%) | 5.3 ± 4.5     | 57 ± 7 |
| Hof et al.9            | 79                 | 12 ± 5            | 55 (70%)      | 20 (25%)      | 4 (5%)       | 56 ± 8       | 60 (76%) | 8 ± 6         | NA    |
| Lo et al.10            | 16 (ZF)            | 27 ± 3            | NA            | 49 ± 2        | 15 (94%)     | 9 ± 2        | 55 ± 2    |               |       |
|                       | 20 (CX)            | 27 ± 3            | NA            | 54 ± 2        | 18 (90%)     | 7 ± 1        | 54 ± 2    |               |       |
|                       |                    |                   |               |               |              |              |     |                |       |
| Kuppahally et al.11    | 31 (LF)            | 6 ± 3             | NA            | 57 ± 15       | (80%)        | NA           | 52 ± 12   |               |       |
|                       | 37                 |                   | NA            | 66 ± 13       | (59%)        | NA           | 52 ± 11   |               |       |
|                       |                    |                   |               |               |              |              |     |                |       |
| Donal et al.12         | 31                 | 12                | 31 (100%)     | 56.4 ± 10     | 25 (80%)     | 20 (80%)     | NA        | NA            |       |
|                       |                    |                   |               |               |              |              |     |                |       |
| Nori et al.13          | 29                 | 3                 | 16            | 54 ± 11       | 11 (69%)     | 4.1 ± 3.4    | 56.0 ± 4.5|               |       |
|                       |                    |                   | 13            | 58 ± 10       | 7 (54%)      | 2.0 ± 1.0    | 52.9 ± 10|               |       |
|                       |                    |                   |               |               |              |              |     |                |       |
| Dagres et al.14        | 289                | 12                | 289           | NA            | NA           | 56 ± 9       | NA        | NA            |       |
| Rodrigues et al.15     | 33                 | 8                 | 33            | 55 ± 13       | 22 (79%)     | 6           | NA        |               |       |
| Choi et al.16          | 33                 | 3                 | 21 (64%)      | 56 ± 10       | 27 (82%)     | 5 ± 4        | 53 ± 6    |               |       |
| Liu et al.17           | 120                | 12                | 60 (50%)      | 59 ± 9        | 40 (67%)     | 2.6 ± 1      | 67 ± 3    |               |       |
|                       |                    |                   | 60 (50%)      | 60 ± 9        | 40 (67%)     | 2.6 ± 1      | 66 ± 4    |               |       |
|                       |                    |                   |               |               |              |              |     |                |       |
| Marsan et al.18        | 57                 | 8                 | 45 (79%)      | 56 ± 9        | 44 (77%)     | 4.6 ± 4.1    | 57 ± 9    |               |       |
| Study                  | Number of patients | Follow-up (month) | Paroxysmal AF | Persistent AF | Permanent AF | Age (years) | Men    | Duration of AF | LVEF |
|-----------------------|--------------------|-------------------|---------------|---------------|--------------|-------------|--------|----------------|------|
| Müller et al.19       | 91                 | 6                 | 72 (79%)      | 11 (12%)      | 8 (9%)       | 59 ± 8      | 79 (87%)| 6.4 ± 6        | NA   |
| Wylie et al.20        | 33                 | 1.5               | 24 (73%)      | 9 (27%)       | NA           | 55 ± 12     | 25 (76%)| 5              | 64 ± 7|
| Schneider et al.21    | 118                | 3                 | 74            | 44            | NA           | NA          | 25 (76%)| 64 ± 7         |
| Delgado et al.22      | 34                 | 6                 | 23 (68%)      | 6 (18%)       | 5 (15%)      | 53 ± 13     | 24 (70%)| 7 ± 6          | NA   |
| Efremidis et al.23    | 13                 | 9                 | NA            | 10 (76.9%)    | 2 (23.1%)    | 55 ± 23     | 11 (84.6%)| 3.2 ± 2.4      | 35   |
| Perea et al.24        | 55                 | 12                | 41 (74%)      | 14 (26%)      | NA           | 52 ± 11     | 44 (80%)| 8.4 ± 8        | 60 ± 9|
| Verma et al.25        | 26                 | 6                 | 40 (60%)      | 27 (40%)      | NA           | 56 ± 10     | 19 (73%)| 5.8 ± 5        | 50 ± 13|
| Tops et al.26         | 57                 | 3                 | 35 (61%)      | 18 (32%)      | 4 (7%)       | 53 ± 8      | 45 (79%)|               |      |
| Beukema et al.27      | 105                | 15                | 52 (49%)      | 53 (51%)      | NA           | 53 ± 9      | 88 (84%)| 6 ± 5          | 54 ± 4|
| Lemola et al.28       | 27                 | 5                 | 27 (75%)      | NA            | 9 (25%)      | 55 ± 11     | 18 (66%)| 5 ± 4          | 56 ± 5|
| Jayam et al.29        | 51                 | 2                 | 28 (55%)      | 12 (33%)      | NA           | 53 ± 16     | 37 (73%)| 8.5 ± 6.5      | 59 ± 6|
| Reant et al.30        | 48                 | 11                | 37 (77%)      | 30 (75%)      | NA           | 53 ± 9      | 6 ± 5   | 62 ± 5         |      |
|                       |                    |                   | NA            | NA            | NA           | NA         | NA     | NA             | NA   |
|                       |                    |                   | 11 (23%)      | 55 ± 11       | 10 (91%)     | 12 ± 9      | NA     | NA             |      |
| Tsao et al.31         | 45                 | 21                | 45 (100%)     | NA            | NA           | 60 ± 13     | 36 (80%)| NA             | NA   |
| Lemola et al.32       | 41                 | 4                 | 25 (61%)      | NA            | 16 (39%)     | 54 ± 12     | 33 (80%)| 5 ± 3          | 55 ± 8|

R: responder (LAVmax after ablation decrease ≥ 15%); NR: non-responder; RE: recurrence of AF; LF: left atrial wall fibrosis <10%; ZF: paroxysmal AF; CX: nonparoxysmal AF.
Table 4. Primary outcome variables before & after ablation of studies included in the meta-analysis.

| Study             | Study | LAD before CA | LAD after CA | LAVmax before CA | LAVmax after CA | LAVmin before CA | LAVmin after CA | LEAF/LAAEF before CA | LEAF/LAAEF after CA | LA strain before CA | LA strain after CA |
|-------------------|-------|---------------|--------------|------------------|-----------------|------------------|-----------------|---------------------|---------------------|---------------------|---------------------|
| Montserrat et al.  | 7     | 43 ± 6        | 42 ± 6       | 52 ± 17          | 50 ± 19         | 38 ± 18          | 33 ± 15         | 35 ± 17/25 ± 14      | 36 ± 17/24 ± 16      | NA                  | NA                  |
|                   | 8     | 43 ± 6        | 42 ± 6       | 57 ± 18          | 52 ± 18         | 37 ± 17          | 35 ± 15         | 34 ± 15/18 ± 15      | 34 ± 15/18 ± 15      | NA                  | NA                  |
| Tops et al.       | 8     | NA            | NA           | NA               | NA              | NA               | NA             | 41 ± 13             | 45 ± 14             | 17 ± 7              | 19 ± 9              |
|                   |       | 43 ± 4 (R)    | 40 ± 4 (R)   | NA               | NA              | NA               | NA             | 41 ± 14 (R)         | 46 ± 11 (R)         | 19 ± 8 (R)          | 22 ± 9 (R)          |
|                   |       | 43 ± 5 (NR)   | 45 ± 6 (NR)  | NA               | NA              | NA               | NA             | 41 ± 12 (NR)        | 42 ± 18 (NR)        | 14 ± 6 (NR)         | 15 ± 8 (NR)         |
| Hof et al.        | 9     | 43 ± 6        | NA           | 104 ± 27         | 91 ± 25         | NA               | NA             | NA                  | NA                  | NA                  | NA                  |
|                   |       |               |              | 103 ± 27         | 89 ± 24         | NA               | NA             | NA                  | NA                  | NA                  | NA                  |
|                   |       |               |              | 105 ± 29 (RE)    | 95 ± 27 (RE)    | NA               | NA             | NA                  | NA                  | NA                  | NA                  |
| Lo et al.         | 10    | 42 ± 2 (ZF)   | 40 ± 2       | 72 ± 8           | NA              | NA               | NA             | NA                  | NA                  | NA                  | NA                  |
|                   |       | 45 ± 2 (CX)   | 46 ± 1       | 108 ± 7          | 114 ± 8         | NA               | NA             | NA                  | NA                  | NA                  | NA                  |
| Kuppahally et al. | 11    | 41 ± 7 (LF)   | 36 ± 6       | NA               | NA              | NA               | NA             | 47 ± 16             | 48 ± 12             | 31 ± 16             | 41 ± 11             |
|                   | 11    | 41 ± 8        | 39 ± 7       | NA               | NA              | NA               | NA             | 43 ± 16             | 48 ± 14             | 29 ± 15             | 34 ± 19             |
| Kuppahally et al. | 12    | 41 ± 7        | 38 ± 7       | NA               | NA              | NA               | NA             | 44 ± 16             | 51 ± 12             | 31.8 ± 17.1         | 40.5 ± 16.3         |
|                   |       | 43 ± 7 (RE)   | 41 ± 6 (RE)  | 46 ± 15          | 41 ± 13         | 24.5 ± 15.6      | 30.8 ± 17.9    | NA                  | NA                  | NA                  | NA                  |
| Donal et al.      | 12    | 49 (45.55)    | 42 (39.46)   | 80 (61.120)      | 62 (53.95)      | 50 (40.50)       | 50 (50.60)      | NA                  | NA                  | NA                  | NA                  |
| Nori et al.       | 13    | NA            | 37.0 ± 6.4/m²| 28.5 ± 5.9      | 19.7 ± 5.7      | 16.3 ± 5.9       | 47.3 ± 10.1    | 42.7 ± 9.4          | NA                  | NA                  | NA                  |
|                   |       |               |              |                  | 33.4 ± 8.3      |                  |                |                     |                     |                     | /26.2 ± 7.9         |
|                   |       |               |              |                  | 41.4 ± 8.7      |                  |                |                     |                     |                     | 34.8 ± 10.2         |
| Dagres et al.     | 14    | 42 ± 6        | 41 ± 6       | 36.7 ± 10.0      | 31.7 ± 9.3      | 24.0 ± 8.8       | 24.1 ± 11.8     | 34.8 ± 10.2         | 34.8 ± 10.2         | 42 ± 5              | 42 ± 5              |

(continued)
| Study               | LAD before CA | LAD after CA | LAVmax before CA | LAVmax after CA | LAVmin before CA | LAVmin after CA | LAEF/LAAEF before CA | LEAF/LAAEF after CA | LA strain before CA | LA strain after CA |
|---------------------|----------------|---------------|-------------------|-----------------|------------------|-----------------|----------------------|---------------------|---------------------|--------------------|
| Rodrigues et al.15  | 41 ± 7         | 40 ± 6        | 55 ± 18           | 57 ± 19         | 30 ± 15          | 34 ± 15         | 47 ± 81              | 43 ± 81              | NA                  | NA                 |
|                     |                |               | 56 ± 21           | 58 ± 20         |                  |                 |                      |                     |                     |                    |
|                     |                |               | 53 ± 14 (RE)      | 57 ± 20 (RE)    |                  |                 |                      |                     |                     |                    |
| Choi et al.16       | NA             | NA            | 63 ± 20           | 50 ± 16         | 44 ± 18          | 35 ± 13         | 32 ± 12              | 31 ± 10              | NA                  | NA                 |
|                     |                |               | 33 ± 3            | 32 ± 2          | NA               | NA              | NA                   | NA                  | NA                  | NA                 |
| Liu et al.17        | 35 ± 3 (RE)    | 35 ± 3 (RE)   | NA                | NA              | NA               | NA              | NA                   | NA                  | NA                  | NA                 |
| Liu et al.17        | 35 ± 2 (RE)    | 35 ± 2 (RE)   | NA                | NA              | NA               | NA              | NA                   | NA                  | NA                  | NA                 |
| Marsan et al.18     | NA             | NA            | 26 ± 8            | 23 ± 7          | 13 ± 5           | 10 ± 4          | 52 ± 10              | 58 ± 10              | NA                  | NA                 |
|                     | NA             | NA            | 31 ± 8 (RE)       | 32 ± 8 (RE)     | 16 ± 7 (RE)      | 18 ± 6 (RE)     | 47 ± 13 (RE)         | 42 ± 11 (RE)         | NA                  | NA                 |
| Muller et al.19     | 45 ± 3         | 42 ± 2        | 59 ± 12           | 50 ± 11         | 37 ± 9           | 31 ± 7          | NA                   | NA                  | NA                  | NA                 |
|                     | 45 ± 3 (RE)    | 48 ± 3 (RE)   | 63 ± 7 (RE)       | 68 ± 8 (RE)     | 43 ± 7 (RE)      | 47 ± 7 (RE)     | NA                   | NA                  | NA                  | NA                 |
| Wylie et al.20      | NA             | NA            | 120 ± 32          | 102 ± 25        | 62 ± 23          | 58 ± 19         | /31 ± 10             | /27 ± 8              | NA                  | NA                 |
| Schneider et al.21  | 30 (Zf)        | 30 (Zf)       |                  |                 |                 |                 |                      |                     |                     |                    |
|                     | 25 (CX)        | 25 (CX)       |                  |                 |                 |                 |                      |                     |                     |                    |
| Delgado et al.22    | NA             | NA            | 55 ± 16           | 48 ± 16         | 28 ± 13          | 26 ± 11         | 49 ± 16/25 ± 20      | 46 ± 13/28 ± 18      | NA                  | NA                 |
| Efremidis et al.23  | 49 ± 5         | 44 ± 4        | NA                | NA              | NA               | NA              | NA                   | NA                  | NA                  | NA                 |
|                     | 49 ± 10 (RE)   | 48 ± 9 (RE)   | NA                | NA              | NA               | NA              | NA                   | NA                  | NA                  | NA                 |
| Perea et al.24      | 98 ± 20        | 85 ± 17       | 58 ± 16           | 52 ± 12         | 40 ± 111         | 38 ± 111        | NA                   | NA                  | NA                  | NA                 |
|                     | 126 ± 33 (RE)  | 103 ± 28 (RE) | 78 ± 22 (RE)      | 76 ± 24 (RE)    | 37 ± 101 (RE)    | 27 ± 101 (RE)   |                      |                     |                     |                    |

(continued)
| Study              | LAD before CA | LAD after CA | LAVmax before CA | LAVmax after CA | LAVmin before CA | LAVmin after CA | LAEFLAAEF before CA | LEAFLAAEF after CA | LA strain before CA | LA strain after CA |
|--------------------|---------------|--------------|------------------|------------------|------------------|------------------|---------------------|---------------------|---------------------|---------------------|
| Verma et al.       | NA            | NA           | 94 ± 28          | 86 ± 18          | 78 ± 24          | 67 ± 14          | 17 ± 6              | 22 ± 5              | NA                  | NA                  |
| Tops et al.        | 45 ± 3        | 42 ± 2       | 59 ± 12          | 50 ± 11          | 37 ± 9           | 31 ± 7           | NA                  | NA                  | NA                  | NA                  |
|                    | 45 ± 3 (RE)   | 48 ± 3 (RE)  | 63 ± 7 (RE)      | 68 ± 8 (RE)      | 43 ± 7 (RE)      | 47 ± 7 (RE)      |                     |                     |                     |                     |
| Beukema et al.     | 40 ± 4 (ZF)   | 37 ± 3       | NA               | NA               | NA               | NA               | NA                  | NA                  | NA                  | NA                  |
|                    | 44 ± 6 (CX)   | 40 ± 4       | 45 ± 6CX (RE)    | 49 ± 5 (RE)      | 45 ± 6CX (RE)    | 49 ± 5 (RE)      |                     |                     |                     |                     |
| Lemola et al.      | NA            | NA           | 121 ± 40         | 95 ± 30          | 87 ± 39          | 78 ± 27          | 32 ± 13 (ZF)       | 21 ± 8 (ZF)         | NA                  | NA                  |
| Jayam et al.       | 36 ± 6        | 34 ± 8       | 102 ± 42         | 84 ± 30          | NA               | NA               | NA                  | NA                  | NA                  | NA                  |
| Reant et al.       | NA            | NA           | NA               | NA               | NA               | NA               | /31 ± 13 (ZF)       | /34 ± 11 (ZF)       | NA                  | NA                  |
|                    |               |              |                  |                  |                  |                  | /5.5 ± 4 (CX)       | /22 ± 11 (CX)       |                     |                     |
| Tsao et al.        | 64 ± 8        | 61 ± 9       | 61 ± 19          | 56 ± 17          | NA               | NA               | NA                  | NA                  | NA                  | NA                  |
|                    | 63 ± 8 (RE)   | 68 ± 11 (RE) | 61 ± 17 (RE)     | 78 ± 25 (RE)     | 63 ± 8 (RE)      | 68 ± 11 (RE)     | 61 ± 17 (RE)       | 78 ± 25 (RE)        | NA                  | NA                  |
| Lemola et al.      | NA            | NA           | 115 ± 39         | 97 ± 35          | NA               | NA               | NA                  | NA                  | NA                  | NA                  |
|                    |               |              | 128 ± 80 (RE)    | 135 ± 70 (RE)    | 128 ± 80 (RE)    | 135 ± 70 (RE)    |                     |                     |                     |                     |

R: responder (LAVmax after ablation decrease ≥ 15%); NR: non-responder; RE: recurrence of AF; LF: left atrial wall fibrosis < 10%; ZF: paroxysmal AF; CX: nonparoxysmal AF.
Figure 2. Forest plot of comparison of change in LAD before ablation and after ablation at follow-up.
**Figure 3.** Forest plot of comparison of change in LAVmax before ablation and after ablation at follow-up.

| Study of sub-category | Before ablation (Mean [SD]) | After ablation (Mean [SD]) | WMD (random) 95% CI | Weight % | WMD (random) 95% CI |
|-----------------------|-----------------------------|-----------------------------|---------------------|----------|---------------------|
| **01 LAVmax changes in patients with AF recurrence** |
| Hof2011               | 96.00 (27.00)               | 106.00 (29.00)              | 2.09                | -10.00   | [-28.84, 8.84]      |
| Lemola 2004           | 139.00 (70.00)              | 128.00 (80.00)              | 0.13                | 7.00     | [-64.18, 100.16]    |
| Marsan 2008           | 92.00 (8.00)                | 81.00 (8.00)                | 6.46                | 1.00     | [-4.09, 4.09]       |
| Moller 2008           | 59.00 (8.00)                | 50.00 (8.00)                | 6.59                | 5.00     | [0.46, 9.66]        |
| Perea 2008            | 103.00 (28.00)              | 89.00 (14.00)               | 2.00                | -23.00   | [-42.46, 6.94]      |
| Rodrigues 2009        | 57.00 (20.00)               | 59.00 (14.00)               | 2.88                | 4.00     | [-20.48, 18.48]     |
| Tosa 2006             | 69.00 (8.00)                | 63.00 (7.00)                | 5.49                | 5.00     | [0.09, 9.91]        |
| Subtotal (95% CI)     | 120                         | 120                         | 25.72               | 2.46     | [-2.08, 7.00]       |
| Test for heterogeneity: Chi² = 12.78, df = 7 (P = 0.08), η² = 45.2% |
| Test for overall effect: Z = 1.68 (P = 0.29) |

| **02 LAVmax changes in patients with NO AF recurrence** |
| Hof2011               | 89.00 (24.00)               | 108.00 (27.00)              | 4.29                | -14.00   | [-22.99, 4.91]      |
| Lemola 2004           | 89.00 (38.00)               | 115.00 (39.00)              | 2.90                | -19.00   | [-35.12, -2.93]     |
| Marsan 2008           | 23.00 (7.00)                | 26.00 (8.00)                | 5.86                | -3.00    | [-6.88, 0.38]       |
| Moller 2008           | 80.00 (11.00)               | 89.00 (12.00)               | 4.77                | -9.00    | [-12.81, -5.19]     |
| Perea 2008            | 88.00 (17.00)               | 98.00 (20.00)               | 4.76                | -13.00   | [-20.80, -5.80]     |
| Rodrigues 2009        | 88.00 (20.00)               | 86.00 (21.00)               | 3.02                | 2.00     | [-11.79, 16.79]     |
| Tosa 2005             | 80.00 (11.00)               | 89.00 (12.00)               | 6.44                | -9.00    | [-14.11, -4.39]     |
| Subtotal (95% CI)     | 944                         | 944                         | 35.96               | 9.00     | [-11.46, -5.64]     |
| Test for heterogeneity: Chi² = 15.24, df = 7 (P = 0.03), η² = 54.1% |
| Test for overall effect: Z = 4.53 (P < 0.0001) |

| **03 LAVmax changes in all patients** |
| Choi 2009             | 80.00 (16.00)               | 63.00 (20.00)               | 4.37                | -13.00   | [-21.74, -4.66]     |
| Donal 2010            | 82.00 (38.00)               | 80.00 (30.00)               | 2.77                | -18.00   | [-32.93, -3.07]     |
| Hof 2011              | 91.00 (28.00)               | 104.00 (27.00)              | 4.63                | -13.00   | [-23.11, -2.99]     |
| Jayam 2005            | 84.00 (20.00)               | 102.00 (42.00)              | 2.84                | -18.00   | [-32.17, -2.63]     |
| Lemola 2005           | 95.00 (30.00)               | 121.00 (40.00)              | 2.08                | -26.00   | [-44.46, -7.14]     |
| Lo 2011               | 88.00 (8.00)                | 108.00 (7.00)               | 5.56                | 6.00     | (1.54, 10.66)       |
| Montserrat 2011       | 97.00 (19.00)               | 98.00 (19.00)               | 4.80                | -8.00    | [-12.90, -3.10]     |
| Rodrigues 2009        | 87.00 (18.00)               | 85.00 (18.00)               | 4.31                | 2.00     | [-6.93, 10.98]      |
| Verma 2005            | 86.00 (18.00)               | 94.00 (28.00)               | 3.28                | -8.00    | [-20.79, 4.79]      |
| Wylie 2005            | 102.00 (28.00)              | 120.00 (32.00)              | 3.00                | -18.00   | [-31.88, -4.18]     |
| Subtotal (95% CI)     | 437                         | 437                         | 30.76               | -9.87    | [-16.41, -3.32]     |
| Test for heterogeneity: Chi² = 46.66, df = 9 (P < 0.00001), η² = 80.7% |
| Test for overall effect: Z = 2.96 (P = 0.003) |

Total (95% CI) 901 901 100.00 -6.12 [-9.45, 2.78]
Figure 4. Forest plot of comparison of change in LAVmin before ablation and after ablation at follow-up.
Figure 5. Forest plot of comparison of change in LAEF/LAAEF before ablation and after ablation.
Figure 6. Forest plot of comparison of change in LA strain before ablation and after ablation.
does not change after RFCA. When studies were separately analysed on the basis of AF recurrence, we found that, in patients with AF recurrence, there were no significant decreases in LAD and LA volumes after RFCA. More importantly, there were significant decreases in the LAEF/LAAEF in patients with AF recurrence after ablation therapy. In contrast, in patients without AF recurrence, RFCA therapy clearly decreased LA size and volumes, and there was no change in LAEF/LAAEF. It seems that LA strain increases in patients without AF recurrence, with less fibrosis and with more LA volumes decrease, but the differences were not significant.

**Interpretation of findings in relation to previously published work**

There are many factors that could influence the structural and functional remodeling of left atrium after RFCA. Those factors included the amount of LA scar produced by RFCA, or LA fibrosis before ablation and restoration of sinus rhythm and/or reduction of AF burden (defined as the frequency times the duration of AF). Currently, the amount of RFCA in different areas of the left atrium required for creating an ideal scar volume that would prevent AF recurrence and not decrease LA function are unknown. Hall et al.\(^3\) showed that wall thickness of LA is variable and the roof and posterior wall are thinnest. Recently, Peters et al.\(^4\) showed that patients with more RFCA scars in the right inferior pulmonary vein area had less AF recurrence than those with fewer scars in the same area. But Wylie et al.\(^2\) showed that excessive scar volume decreased the LA function. Also, there are studies that showed that the extent of LA wall injury correlates with arrhythmia recurrence at three months.\(^3\) So, the recovery of LA function after RFCA is a comprehensive result of amount of LA scar tissue and the restoration of sinus rhythm and/or a reduction in AF burden. It is difficult to distinguish whether the decrease in LA function in those with AF recurrence after RFCA is related to the continued presence of AF (any AF or some magnitude of AF burden) or excessive scar tissue produced by RFCA therapy.

The time of research of LA function or LA dimensions is another important factor that needs more attention. Studies with longer durations of follow-up\(^5,6,16,22,30\) have found no significant increases in LA function, whereas studies with shorter durations of follow-up\(^2\) have shown decreases in LA function. Our sensitivity analysis on the basis of the duration of follow-up did not get a conclusion, which may be caused by different sample size and lack of individual patient data. Studies have found that the detection and quantification of LA scar is feasible three months after RFCA.\(^3,36\) Therefore, LA function should be evaluated over a longer duration of

**Figure 7.** Funnel plot of change in LAD before ablation and after ablation at follow-up.

![Funnel plot of change in LAD before ablation and after ablation at follow-up.](image)
follow-up. Future studies should consider the timing of LA functional assessments as an important factor in their study designs and allow adequate time for the recovery of LA function.

Another challenge about studying LA function is in patients with permanent AF. Because LA function could not be accurately assessed in AF rhythm, one possible way to assess baseline LA function of patients with chronic AF is to measure it within three to six months after RFCA.30

What is more, the method to determine LA function is of upmost importance. Until now, there is no standardization in the measurement of LA function. During the initial part of left ventricular diastole, the left atrium has a passive conduit function, whereas it has an active pump or booster function during the later part of ventricular diastole, as the atrium contracts. More importantly, the imaging techniques used in these studies were different and included two-dimensional trans-thoracic echocardiography, three-dimensional trans-thoracic echocardiography, computed tomography with three-dimensional reconstruction and cardiac magnetic resonance imaging. Although echocardiography is an established tool in cardiac imaging, it has significant limitations in patients with poor acoustic windows, such as obese patients and those with severe obstructive pulmonary disease. Two-dimensional echocardiography may underestimate true LA size compared to computed tomography or magnetic resonance imaging. Multi-slice computed tomography has excellent spatial and temporal resolution in quantifying LA volumes, but radiation exposure and contrast dye exposure limit its use. Magnetic resonance imaging has unique advantages over other modalities because it can simultaneously measure the pulmonary vein anatomy and detect pre-ablation fibrosis and post-ablation scar in patients who undergo RFCA.37

Our results show that RFCA therapy favours structural remodeling of the left atrium by decreasing size and volumes during follow-up. This is important because LA size and volumes are powerful predictors of cardiovascular outcomes. Increased LA size and volumes are associated with increased risk for developing AF and congestive heart failure. Therefore, a consistent decrease of LA volumes seen across all the studies may be an important outcome of an RFCA procedure. Another important observation, although inconclusive, is that successful RFCA procedures did not adversely affect LA function. It is important to understand the effect of RFCA therapy on LA function because the left atrium modulates left ventricular filling and performance. Moreover, elderly patients are more dependent on LA contraction for left ventricular filling, and a loss of LA function could lead to decreased exercise capacity and an increased incidence of heart failure.

Weaknesses of this study
Our meta-analysis had limitations that deserve further consideration. Variations in study imaging techniques, differences in ablation strategies and different follow-up durations among these studies make it difficult to draw definitive conclusions about LA functional change produced by RFCA. Also, a lack of individual patient data on the post-RFCA duration of sinus rhythm or AF burden and the amount of LA scar makes it difficult to differentiate the effects of RFCA on LA function. Another important limitation is that LA function could be measured only during sinus rhythm. A lack of standardization of measurement of LA function among the included studies is another limitation. Additionally, our systematic review could not distinguish cause from effect. We were unable to distinguish whether the differences in the effects of RFCA on LA size and function cause AF recurrence or whether AF recurrence after RFCA cause the differences in LA size and function. Perhaps studies that methodically analyse scar volume and quantity AF burden will shed light on the cause-and-effect relations.

Declarations
Competing interests: None declared

Funding: This review forms part of a project for which funding was awarded to Ming-long Chen by National Natural Science Foundation of China. The funders played no role in study design, data collection or interpretation, the writing or dissemination of this review.

Ethical approval: As a review of existing data, ethical approval was not required.

Guarantor: MLC

Contributorship: Yan Zhuang and Ming-long Chen contributed to study design. Data were collected and analysed by Yan Zhuang and Yong-hong Yong. Yan Zhuang and Ming-long Chen drafted/revised the article. The final version has been approved by all authors.

Acknowledgements: The authors would like to thank Jing Yao, who kindly helped to perform the database search.

Provenance: Not commissioned; peer-reviewed by Julia Ormerod

References
1. Lip GY, Tse HF and Lane DA. Lane atrial fibrillation. Lancet 2012; 379: 648–661.
2. Thomas SP and Sanders P. Catheter ablation for atrial fibrillation. Heart Lung Circ 2012; 21: 395–401.
3. Lee G, Sanders P and Kalman JM. Catheter ablation of atrial arrhythmias: state of the art. *Lancet* 2012; 380: 1509–1519.

4. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Heart Rhythm* 2011; 8: 157–176.

5. Jeevanantham V, Ntim W, Navaneethan SD, Shah S, Johnson AC, Hall B, et al. Meta-analysis of the effect of radiofrequency catheter ablation on left atrial size, volumes and function in patients with atrial fibrillation. *Am J Cardiol* 2010; 105: 1317–1326.

6. Moher D, Liberati A, Tetzlaff J, Altman DG and Group PRISMA. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009; 62: 1006–1012.

7. Montserrat S, Sitges M, Calvo N, Silva E, Tamborero D, Vidal B, et al. Effect of repeated radio-frequency catheter ablation on left atrial function for the treatment of atrial fibrillation. *Am J Cardiol* 2011; 108: 1741–1746.

8. Tops LF, Delgado V, Bertini M, Marsan NA, Den Uijl DW, Trines SA, et al. Left atrial strain predicts reverse remodeling after catheter ablation for atrial fibrillation. *J Am Coll Cardiol* 2011; 57: 324–331.

9. Hof IE, Veltbuis BK, Chaldoupi SM, Wittkampf FH, van Driel VJ, van der Heijden JF, et al. Pulmonary vein antrum isolation leads to a significant decrease of left atrial size. *Europace* 2011; 13: 371–375.

10. Lo LW, Tsao HM, Lin YJ, et al. Different patterns of atrial remodeling after catheter ablation of chronic atrial fibrillation. *J Cardiovasc Electrophysiol* 2011; 22: 385–393.

11. Kuppahally SS, Akoum N, Badger TJ, Burgon NS, Haslam T, Kholmovskii E, et al. Echocardiographic left atrial reverse remodeling after catheter ablation of atrial fibrillation is predicted by preablation delayed enhancement of left atrium by magnetic resonance imaging. *Am Heart J* 2010; 160: 877–884.

12. Donal E, Ollivier R, Veillard D, Hamonic S, Pavin D, Daubert JC, et al. Left atrial function assessed by trans-thoracic echocardiography in patients treated by ablation for a lone paroxysmal atrial fibrillation. *Eur J Echocardiogr* 2010; 11: 845–852.

13. Nori D, Raff G, Gupta V, Gentry R, Boura J and Haines DE. Cardiac magnetic resonance imaging assessment of regional and global left atrial function before and after catheter ablation for atrial fibrillation. *J Interv Card Electrophysiol* 2009; 26: 109–117.

14. Dagres N, Hindricks G, Kottkamp H, Varounis C, Bode K, Arya A, et al. Effect of atrial fibrillation ablation on left atrial contractile function in patients with paroxysmal atrial fibrillation and a relatively well preserved atrial function. *Acta Cardiol* 2009; 64: 167–169.

15. Rodrigues AC, Scannavacca MI, Caldas MA, Hotta VT, Pisaní C, Sosa EA, et al. Left atrial function after ablation for paroxysmal atrial fibrillation. *Am J Cardiol* 2009; 103: 395–398.

16. Choi JI, Park SM, Park JS, Hong SJ, Pak HN, Lim do S, et al. Changes in left atrial structure and function after catheter ablation and electrical cardioversion for atrial fibrillation. *Circ J* 2008; 72: 2051–2057.

17. Liu Z, Ling Z, Su L, Wu J, Lan X, Chen Y, et al. The effect of different treatment strategies on left atrial size in patients with lone paroxysmal atrial fibrillation – a prospective cohort study. *J Interv Card Electrophysiol* 2008; 23: 167–173.

18. Marsan NA, Tops LF, Holman ER, Van de Veire NR, Zeppenfeld K, Boersma E, et al. Comparison of left atrial volumes and function by real-time three-dimensional echocardiography in patients having catheter ablation for atrial fibrillation with persistence of sinus rhythm versus recurrent atrial fibrillation three months later. *Am J Cardiol* 2008; 102: 847–853.

19. Müller H, Noble S, Keller PF, Sigaud P, Gentil P, Lerch R, et al. Biaatrial anatomical reverse remodelling after radiofrequency catheter ablation for atrial fibrillation: evidence from real-time three-dimensional echocardiography. *Europace* 2008; 10: 1073–1078.

20. Wylie JV Jr, Peters DC, Essebag V, Manning WJ, Josephson ME and Hauser TH. Left atrial function and scar after catheter ablation of atrial fibrillation. *Heart Rhythm* 2008; 5: 656–662.

21. Schneider C, Malisius R, Krause K, Lampe F, Bahlmann E, Boczor S, et al. Strain rate imaging for functional quantification of the left atrium: atrial deformation predicts the maintenance of sinus rhythm after catheter ablation of atrial fibrillation. *Eur Heart J* 2008; 29: 1397–1409.

22. Delgado V, Vidal B, Sitges M, Tamborero D, Mont L, Berruezo A, et al. Fate of left atrial function as determined by real-time three-dimensional echocardiography study after radiofrequency catheter ablation for the treatment of atrial fibrillation. *Am J Cardiol* 2008; 101: 1285–1290.

23. Efremidis M, Sideris A, Xydonas S, Letsas KP, Alexianan IP, Manolatos D, et al. Ablation of atrial fibrillation in patients with heart failure: reversal of atrial and ventricular remodelling. *Hellenic J Cardiol* 2008; 49: 19–25.

24. Perea RJ, Tamborero D, Mont L, De Caralt TM, Ortiz JT, Berruezo A, et al. Left atrial contractility is preserved after successful circumferential pulmonary vein ablation in patients with atrial fibrillation. *J Cardiovasc Electrophysiol* 2008; 19: 374–379.

25. Verma A, Kilicaslan F, Adams JR, Hao S, Beheiry S, Minor S, et al. Extensive ablation during pulmonary vein antrum isolation has no adverse impact on left atrial function: an echocardiography and cine computed tomography study. *J Cardiovasc Electrophysiol* 2006; 17: 741–746.

26. Tops LF, Bax JJ, Zeppenfeld K, Jongbloed MR, van der Wall EE and Schalij MJ. Effect of radiofrequency catheter ablation for atrial fibrillation on left atrial cavity size. *Am J Cardiol* 2006; 97: 1220–1222.
27. Beukema WP, Elvan A, Sie HT, Misier AR and Wellens HJ. Successful radiofrequency ablation in patients with previous atrial fibrillation results in a significant decrease in left atrial size. *Circulation* 2005; 112: 2089–2095.

28. Lemola K, Desjardins B, Sneider M, Case I, Chugh A, Good E, et al. Effect of left atrial circumferential ablation for atrial fibrillation on left atrial transport function. *Heart Rhythm* 2005; 2: 923–928.

29. Jayam VK, Dong J, Vasamreddy CR, Lickfett L, Kato R, Dickfeld T, et al. Atrial volume reduction following catheter ablation of atrial fibrillation and relation to reduction in pulmonary vein size: an evaluation using magnetic resonance angiography. *J Interv Card Electrophysiol* 2005; 13: 107–114.

30. Reant P, Lafitte S, Jaïs P, Serri K, Weerasooriya R, Hocini M, et al. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. *Circulation* 2005; 112: 2896–2903.

31. Tsao HM, Wu MH, Huang BH, Lee SH, Lee KT, Tai CT, et al. Morphologic remodeling of pulmonary veins and left atrium after catheter ablation of atrial fibrillation: insight from long-term follow-up of three-dimensional magnetic resonance imaging. *J Cardiovasc Electrophysiol* 2005; 16: 7–12.

32. Lemola K, Sneider M, Desjardins B, Case I, Chugh A, Hall B, et al. Effects of left atrial ablation of atrial fibrillation on size of the left atrium and pulmonary veins. *Heart Rhythm* 2004; 1: 576–581.

33. Hall B, Jeewahantham V, Simon R, Filippone J, Vorobiof G and Daubert J. Variation in left atrial transmural wall thickness at sites commonly targeted for ablation of atrial fibrillation. *J Interv Card Electrophysiol* 2006; 17: 127–132.

34. Peters DC, Wyle JV, Hauser TH, Nezafat R, Han Y, Woo JJ, et al. Recurrence of atrial fibrillation correlates with the extent of post-procedural late gadolinium enhancement: a pilot study. *JACC Cardiovasc Imaging* 2009; 2: 308–316.

35. McGann CJ, Kholmovski EG, Oakes RS, Blauer JJ, Daccarett M, Segerson N, et al. New magnetic resonance imaging-based method for defining the extent of LA wall injury after the ablation of atrial fibrillation. *J Am Coll Cardiol* 2008; 52: 1263–1271.

36. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. *Circulation* 2009; 119: 1758–1767.

37. Ramakrishna H, Feinglass N and Augoustides JG. Clinical update in cardiac imaging including echocardiography. *J Cardiothorac Vasc Anesth* 2010; 24: 371–378.